Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Passes Above Two Hundred Day Moving Average – Should You Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.46 and traded as high as $4.63. Cumberland Pharmaceuticals shares last traded at $4.53, with a volume of 79,273 shares changing hands.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on CPIX shares. Wall Street Zen upgraded shares of Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Cumberland Pharmaceuticals Stock Down 0.9%

The company has a debt-to-equity ratio of 0.25, a current ratio of 0.95 and a quick ratio of 0.84. The firm has a market capitalization of $67.86 million, a price-to-earnings ratio of -9.24 and a beta of -0.06. The stock has a fifty day moving average of $3.49 and a two-hundred day moving average of $3.46.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings data on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.13). Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.The company had revenue of $9.13 million during the quarter, compared to the consensus estimate of $8.50 million.

Institutional Trading of Cumberland Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its stake in shares of Cumberland Pharmaceuticals by 1.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company’s stock valued at $898,000 after acquiring an additional 4,081 shares in the last quarter. Bridgeway Capital Management LLC increased its stake in shares of Cumberland Pharmaceuticals by 2.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after acquiring an additional 4,200 shares in the last quarter. Two Sigma Investments LP increased its stake in shares of Cumberland Pharmaceuticals by 16.5% in the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after acquiring an additional 5,326 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Cumberland Pharmaceuticals by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after acquiring an additional 5,653 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Cumberland Pharmaceuticals in the 2nd quarter valued at $34,000. Institutional investors own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.